Harvesting peripheral blood progenitor cells from healthy donors: retrospective comparison of filgrastim and lenograstim

Abstract

Mobilization of CD34+ into peripheral blood is attained by either glycosylated (lenograstim) or non-glycosylated recombinant G-CSF (filgrastim). 101 donors, 57 males, median age 42 years (range 16-63) entered this retrospective study. Group I (55 cases) received filgrastim and group II lenograstim subcutaneously for 5-6 days. The peak number of CD34+ cells/microl blood observed on day 4 and 5 was not significantly different in the two groups. No differences were shown in terms of both circulating CFU-GM at the time of harvesting and CD34+ target of collection. The most frequent side effects were bone pain (18.2% grade I; 36.4% grade II, 7.3% grade III), headache (18.2%), nausea (9.1%), fever (5.5%) and a mild splenomegaly (> 2 cm) (5.5%) in filgrastim group, and bone pain (37.0% grade I, 26.1% grade II, 2.2% grade III), headache (17.4%), nausea (15.2%), fever (4.4%) and a mild splenomegaly (4.3%) in lenograstim group, respectively. CD34+ collection was associated with thrombocytopenia, which was not significantly different between the two groups. No donor in either group developed long-term adverse effects. We conclude that both G-CSFs are comparable in terms of CD34+ cell collection, safety and tolerability.

Comparison between filgrastim and lenograstim plus chemotherapy for mobilization of PBPCs

“…In contrast, Martino et al 34 did not find any difference in healthy donors mobilized with glycosylated and non-glycosylated G-CSF. No clear data have been obtained in patients who underwent auto-SCT and who received chemotherapy plus G-CSF during mobilization.…”

Effects of autologous SCF- and G-CSF-mobilized bone marrow stem cells on hypoxia-inducible factor-1 in rats with ischemia-reperfusion renal injury

“…Stem cell factor (SCF) and G-SCF doses were according to an earlier study (Orlic et al, 2001). Because bone marrow mobilization agents usually cause peripheral blood stem cells to peak 3-5 days after treatment (Martion et al, 2005), the fifth day after intervention was chosen as the starting point. In the control group, normal rat kidney tissues were observed.…”

Short and long-term safety of lenograstim administration in healthy peripheral haematopoietic progenitor cell donors: a single centre experience

“…2,3 Avoiding general anaesthesia, surgery (marrow harvesting) and autologous or allogeneic blood transfusions in donors have the potential of making the donation safer, less traumatic and more effective in collecting HPC-A. 4 Although the short-term toxicities of rhG-CSF in donors are well known, [5][6][7][8][9] data on the long-term impact of rhG-CSF in normal donors are scarce, and only a few series involving small numbers of donors have addressed these issues. [10][11][12][13] More widespread use of allogeneic HPC-A may be limited because of the potential risks of the long-term effects of rhG-CSF, [14][15][16][17][18][19][20][21][22] although there are no data in this regard in healthy donors (HDs).…”